Cardiovascular Safety of Cox-2 Inhibitors
Increasing use of rofecoxib (Vioxx) and celecoxib (Celebrex), both selective inhibitors of cyclooxygenase-2 (COX-2), for treatment of arthristis has been accompanied by concerns that they may increase risk of thrombotic cardiovascular events....
Cannot Access - We are sorry, but you cannot access the requested article.
If you have already purchased this article, or have a subscription to The Medical Letter on Drugs and Therapeutics, please login or register to view it online.
If you have already purchased this article, or have a subscription to The Medical Letter on Drugs and Therapeutics, please login or register to view it online.
Information about the article:
Title: Cardiovascular Safety of Cox-2 Inhibitors
Publication: The Medical Letter on Drugs and Therapeutics
Issue #: 1118
Article Code: 1118a
Date: November 12, 2001
Volume: 43
Pages: 99-100
Publication: The Medical Letter on Drugs and Therapeutics
Issue #: 1118
Article Code: 1118a
Date: November 12, 2001
Volume: 43
Pages: 99-100
Subscribe to The Medical Letter on Drugs and Therapeutics for instant access to this article. Add this downloadable, electronic article to your cart (U.S. English version only)